Clinical Trial Update: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial of mapracorat ophthalmic suspension 3% for ocular inflammation after cataract surgery was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation of Eye After Cataract Surgery
• Pain Associated with Ocular Inflammation

Drugs mentioned

• Mapracorat Ophthalmic Suspension 3% (mapracorat)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Inflammation, Pain | Phase 3 | Status: TERMINATED | Results posted: 2020-09-03